A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer.
Z. Hu,J-H Mao,G. Huang,W-L Kuo,M. Lenburg,S. Ziyad,J. Korkola,N. Bayani,N. Wang,S. Gu,B. Weber,R. Wooster,J. Gray
DOI: https://doi.org/10.1158/0008-5472.sabcs-09-2020
IF: 11.2
2009-01-01
Cancer Research
Abstract:Deregulation of aspects of the mitotic apparatus leads to increased genome instability, carcinogenesis and aggressive tumor behavior in human and rodent model systems 1 . This knowledge has stimulated development of inhibitors of elements of the mitotic apparatus as anticancer agents including PLK1, CENPE, and AURKB and several are now being tested for efficacy clincially 2-6 . These trials and eventual clinical use will benefit from molecular markers that predict response. In order to identify such markers, we assessed quantitative responses to the agents GSK461364, GSK923295 and GSK1070916 that target PLK1, CENPE and AURKB; respectively, in a panel of 50 breast cancer cell lines. This analysis showed that basal subtype cell lines were preferentially sensitive to all three agents and that responses among the lines to the three agents were strongly correlated. This may be explained by our discovery that components of the mitotic apparatus including PLK1, CENPE and AURKB form a transcriptionally co-regulated network comprised of more than 50 genes that is preferentially active in basal subtype of breast cell lines and primary tumors. Remarkably, this network also is activate in subsets of cancers of the lung, ovarian, prostate and brain, Wilms tumor, human blood malignancies and selected normal tissues. We then defined a mitotic apparatus network index (MANI) and showed that high MANI was associated with poor outcome clinically and with preferential responsive to GSK461364, GSK923295 and GSK1070916 in preclinical models. This suggests that measures of the MANI will identify poor outcome tumors that will likely respond well to mitotic apparatus network gene inhibitors as well as potential dose limiting normal tissues. Reference 1. Quigley, D.A. et al. Nature 458 , 505-8 (2009).2. Strebhardt, K. & Ullrich, A . Nat. Rev. Cancer 6 , 321-330 (2006).3. Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A. & Nishida, E. Nature 410 , 215-20 (2001).4. Barr, F.A., Sillje, H.H. & Nigg, E.A. Nat. Rev. Mol. Cell. Biol. 5 , 429–440 (2004).5. McInnes, C. et al. Nat. Chem. Biol. 2 , 608–617 (2006).6. Yamada, S. et al. Oncogene 23 , 5901-5911(2004). Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2020.